Abstract

The use of pesticides to reduce mosquito vector populations is a cornerstone of global malaria control efforts, but the biological impact of most pesticides on human populations, including pregnant women and infants, is not known. Some pesticides, including carbamates, have been shown to perturb the human immune system. We measure the systemic absorption and immunologic effects of bendiocarb, a commonly used carbamate pesticide, following household spraying in a cohort of pregnant Ugandan women and their infants. We find that bendiocarb is present at high levels in maternal, umbilical cord, and infant plasma of individuals exposed during pregnancy, indicating that it is systemically absorbed and trans-placentally transferred to the fetus. Moreover, bendiocarb exposure is associated with numerous changes in fetal immune cell homeostasis and function, including a dose-dependent decrease in regulatory CD4 T cells, increased cytokine production, and inhibition of antigen-driven proliferation. Additionally, prenatal bendiocarb exposure is associated with higher post-vaccination measles titers at one year of age, suggesting that its impact on functional immunity may persist for many months after birth. These data indicate that in utero bendiocarb exposure has multiple previously unrecognized biological effects on the fetal immune system.

Control of mosquito populations using pesticides is important for malaria elimination, but effects of pesticides on humans aren’t well understood. Here, Prahl et al. show in a cohort of pregnant Ugandan women and their infants that household spraying with bendiocarb affects the fetal immune system and response to vaccination in infancy.

Details

Title
Exposure to pesticides in utero impacts the fetal immune system and response to vaccination in infancy
Author
Prahl, Mary 1 ; Odorizzi, Pamela 2 ; Gingrich, David 3 ; Muhindo, Mary 4 ; McIntyre, Tara 2 ; Budker Rachel 2 ; Jagannathan Prasanna 5   VIAFID ORCID Logo  ; Farrington Lila 2 ; Mayimuna, Nalubega 4 ; Felistas, Nankya 4 ; Sikyomu Esther 4 ; Musinguzi, Kenneth 4 ; Naluwu Kate 4 ; Auma, Ann 4 ; Kakuru Abel 4 ; Kamya, Moses R 6 ; Dorsey, Grant 2 ; Aweeka Francesca 3 ; Feeney, Margaret E 7   VIAFID ORCID Logo 

 University of California San Francisco, Department of Pediatrics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California San Francisco, Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California San Francisco, Drug Research Unit, Department of Clinical Pharmacy, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Infectious Diseases Research Collaboration, Kampala, Uganda (GRID:grid.463352.5) 
 Stanford University, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Infectious Diseases Research Collaboration, Kampala, Uganda (GRID:grid.463352.5); Makerere University, Department of Medicine, Kampala, Uganda (GRID:grid.11194.3c) (ISNI:0000 0004 0620 0548) 
 University of California San Francisco, Department of Pediatrics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2476252083
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.